These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23075463)

  • 1. Minimizing the passive release of heparin-binding growth factors from an affinity-based delivery system.
    Vo TT; Meere MG
    Math Med Biol; 2013 Dec; 30(4):357-82. PubMed ID: 23075463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release rate controls biological activity of nerve growth factor released from fibrin matrices containing affinity-based delivery systems.
    Wood MD; Sakiyama-Elbert SE
    J Biomed Mater Res A; 2008 Feb; 84(2):300-12. PubMed ID: 17607752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of fibrin derivatives for controlled release of heparin-binding growth factors.
    Sakiyama-Elbert SE; Hubbell JA
    J Control Release; 2000 Apr; 65(3):389-402. PubMed ID: 10699297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity-based drug delivery systems for tissue repair and regeneration.
    Vulic K; Shoichet MS
    Biomacromolecules; 2014 Nov; 15(11):3867-80. PubMed ID: 25230248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury.
    Taylor SJ; McDonald JW; Sakiyama-Elbert SE
    J Control Release; 2004 Aug; 98(2):281-94. PubMed ID: 15262419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.
    Sakiyama-Elbert SE; Hubbell JA
    J Control Release; 2000 Oct; 69(1):149-58. PubMed ID: 11018553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of rationally designed affinity-based drug delivery systems.
    Maxwell DJ; Hicks BC; Parsons S; Sakiyama-Elbert SE
    Acta Biomater; 2005 Jan; 1(1):101-13. PubMed ID: 16701784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical model accurately predicts protein release from an affinity-based delivery system.
    Vulic K; Pakulska MM; Sonthalia R; Ramachandran A; Shoichet MS
    J Control Release; 2015 Jan; 197():69-77. PubMed ID: 25449806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix.
    Han D; Liu W; Ao Q; Wang G
    Med Hypotheses; 2008 Sep; 71(3):374-8. PubMed ID: 18565684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel.
    Jeon O; Kang SW; Lim HW; Hyung Chung J; Kim BS
    Biomaterials; 2006 Mar; 27(8):1598-607. PubMed ID: 16146647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.
    Cai S; Liu Y; Zheng Shu X; Prestwich GD
    Biomaterials; 2005 Oct; 26(30):6054-67. PubMed ID: 15958243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release kinetics of transforming growth factor-beta1 from fibrin clots.
    Giannoni P; Hunziker EB
    Biotechnol Bioeng; 2003 Jul; 83(1):121-3. PubMed ID: 12740939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronate-heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2).
    Liu LS; Ng CK; Thompson AY; Poser JW; Spiro RC
    J Biomed Mater Res; 2002 Oct; 62(1):128-35. PubMed ID: 12124794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled diffusional release of dispersed solute drugs from biodegradable implants of various geometries.
    Collins R; Paul Z; Reynolds DB; Short RF; Wasuwanich S
    Biomed Sci Instrum; 1997; 33():137-42. PubMed ID: 9731349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of diffusion controlled drug delivery.
    Siepmann J; Siepmann F
    J Control Release; 2012 Jul; 161(2):351-62. PubMed ID: 22019555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors.
    Anitua E; Zalduendo MM; Alkhraisat MH; Orive G
    Ann Anat; 2013 Oct; 195(5):461-6. PubMed ID: 23722041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-modified dendrimer crosslinked collagen matrices for the delivery of heparin-binding epidermal growth factor.
    Princz MA; Sheardown H
    J Biomed Mater Res A; 2012 Aug; 100(8):1929-37. PubMed ID: 22492552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
    Klose D; Siepmann F; Elkharraz K; Siepmann J
    Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments.
    Güres S; Siepmann F; Siepmann J; Kleinebudde P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):122-9. PubMed ID: 22008146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of FGF-2 bioactivity using heparin-based nanoparticles, and their delivery from electrospun chitosan fibers.
    Zomer Volpato F; Almodóvar J; Erickson K; Popat KC; Migliaresi C; Kipper MJ
    Acta Biomater; 2012 Apr; 8(4):1551-9. PubMed ID: 22210184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.